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Abstract
Serologic studies are an important diagnostic tool in the clinical evaluation and follow-up of persons with
coccidioidomycosis. Numerous types of serologic tests are available, including immunodiﬀusion, enzyme
immunoassay, and complement ﬁxation. We conducted a retrospective review of the results of 1,797
serologic tests spanning 12 months from the onset of coccidioidomycosis in 298 immunocompetent and 62
immunosuppressed persons with symptomatic infection. Using the onset of symptoms as a reference point,
we plotted the positive or negative serologic results over time for both groups. Compared with the
immunocompetent group, immunosuppressed persons had lower rates of seropositivity for every type of
test during the ﬁrst year after onset of symptoms for coccidioidomycosis, although many results did not
achieve statistical signiﬁcance. Combining the results of these tests increased the sensitivity of the serologic
evaluation in immunocompromised patients. Immunosuppressed persons have the ability to mount a
serologic response to coccidioidomycosis, but in some circumstances, multiple methods may be required to
improve detection.
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Introduction
Coccidioidomycosis is an endemic fungal infection
caused by the Coccidioides species C. immitis [1]
and the recently described, non-California species
C. posadasii [2]. About 60% of persons with these
infections are asymptomatic, and most of the rest
have self-limited pulmonary infections, although a
minority of cases in otherwise healthy persons may
be severe or disseminated [1].
Serologic tests have been used for decades to
assist in the diagnosis and management of coc-
cidioidal infection. Among serologic tests available
for the diagnosis of mycotic illnesses, those used
for coccidioidomycosis are among the most reli-
able [3,4]. At least 7 diﬀerent serologic methods
have been discussed elsewhere [3,5]. Tests com-
monly used in our endemic area include comple-
ment ﬁxation (CF) and immunodiﬀusion (ID) tests
of either tube precipitin antibodies (IgM) or
complement-ﬁxing antibodies (IgG). CF or ID
tests are often performed in reference laboratories.
In addition, an enzyme immunoassay (EIA) to
detect IgG and IgM can be performed in local
clinical laboratories and can often be conﬁrmed by
CF or ID when positive. The EIA for IgG appears
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EIA for IgM may give false-positive results and
should be conﬁrmed with other serologic methods.
Some authors have demonstrated lower rates of
seropositivity in immunosuppressed persons [7–9],
whereas others have reported evidence that the
serologic response is maintained in immunocom-
promised hosts [5,10]; most of these observations
were seen in small case series, had no comparison
group, or contained no temporal information. In
contrast, our report reviews our experience with
each of the 3 serologic methods in both immuno-
competent and immunosuppressed persons as a
function of time since onset of illness.
Materials and methods
Chart review
A retrospective chart review was conducted for all
patients who had coccidioidomycosis diagnosed
between January 1, 1999, and October 31, 2003, at
our tertiary-care academic medical institution.
Patients were identiﬁed by an institutional com-
puter search using ICD-9 (International Classiﬁ-
cation of Diseases, 9th Revision) diagnosis codes
and by a manual search of the reports made to the
Arizona Department of Health Services. Patients
were included only if their records contained ade-
quate documentation of symptoms, laboratory
and microbiologic reports, and pathologic ﬁndings
of coccidioidomycosis. This study was approved
by the Mayo Foundation Institutional Review
Board.
Abstracted information included age, sex, race,
comorbid conditions, dates and results of serologic
tests for coccidioidomycosis, microbiologic tests,
radiographs, and histopathologic tests. Abstracted
information about the clinical coccidioidal syn-
drome included symptoms, location of infection,
treatment, and follow-up.
Deﬁnitions
A patient was deﬁned as having conﬁrmed coccid-
ioidomycosis if C. immitis was isolated from the
culture of any specimen or if any histopathologic
test revealed spherules of Coccidioides spp. Proba-
ble coccidioidomycosis was diagnosed when a
patient had compatible symptoms (e.g., fever,
cough, headache, rash, myalgia, or arthralgia) in
association with compatible radiographic changes
and positive serologic ﬁndings.
Intrathoracic coccidioidomycosis infections
involved any of the following tissues: lung, pleura,
chest wall, or pericardium. Disseminated coccidi-
oidomycosis required a positive culture or positive
histopathologic ﬁnding from a specimen outside
the thoracic cavity.
A patient was considered to be immunocom-
promised if any of the following comorbid
conditions was present: infection with the human
immunodeﬁciency virus, solid organ or hemato-
logic transplant, hematologic malignancy, or
immunosuppression resulting from treatment with
corticosteroids, chemotherapy, or other immuno-
suppressant medications.
Coccidioidal serologic tests
Several coccidioidal serologic tests were conducted.
Our local laboratory performed the EIA to detect
IgM and IgG antibodies using a kit from Meridian
Bioscience, Inc (Cincinnati, Ohio). Positive, inde-
terminate, and negative results were deﬁned
according to the manufacturer’s instructions
(negative = absorbance value<0.150; indetermi-
nate = absorbance value‡0.150 but £ 0.199; or
positive = absorbance value‡0.200).
Serum was also sent to the Mayo Clinic
Infectious Diseases Serology Laboratory, Roche-
ster, Minnesota, to perform the CF and ID tests.
The Laboratory Branch CF test of the Centers
for Disease Control and Prevention was used to
detect IgG antibodies; it has been described pre-
viously [3,11]. As part of this protocol, serum is
concentrated in a standardized fashion. The
antigen for the CF test was obtained from Dr D.
Pappagianis at the University of California at
Davis. Between January 1, 1999, and May 30,
2002, the ID test was performed using a kit from
Gibson Laboratories, Inc (Lexington, Kentucky)
that used antigen F to detect IgG antibodies.
Beginning in June 2002, the ID test was per-
formed using a test kit (Meridian Bioscience, Inc)
to detect both TP (early IgM) antibodies and F
(late IgG) antibodies. To consistently pool the
pre- and post-2002 ID results, we excluded the ID
IgM results obtained after June 2002 from this
analysis. Occasionally, serum samples were sent
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serologic evaluation and conﬁrmation of results.
If a patient manifested an anticomplementary
CF result, the CF test was excluded, although
concurrent ID and EIA results were still included
in the analysis. On occasion, an indeterminate EIA
result was identiﬁed and counted as negative. To
minimize potential false-positive results, we coun-
ted a positive EIA IgM as seropositive only in the
presence of another positive result (either EIA
IgG, ID, CF, or positive microbiologic or histo-
pathologic ﬁndings).
Analysis and statistics
Each serologic result was entered as positive or
negative in 1 of many time intervals from the onset
of symptoms (weeks 1 through 8, and months 2
through 12). Individual patients were counted only
once in any particular interval and were consid-
ered positive for that interval if any serum sample
was positive during that period. Patients without
serologic testing were not included in this analysis.
The percentage of positive assays for each period
was calculated from the number of positive sam-
ples divided by the number of samples submitted
at each interval. Results were graphed as the per-
centage of positive tests over time. Conﬁdence
intervals were calculated for each result in each
time block.
Demographic characteristics were compared
between immunocompromised and nonimmuno-
compromised patients using a v
2 test for categor-
ical variables and a 2-sample t test for continuous
variables. Categorical variables are summarized as
number (percentage; 95% normal binomial conﬁ-
dence interval); continuous variables are presented
as mean±SD and as median (range). In all cases,
a P value of less than .05 is considered statistically
signiﬁcant.
Most of the curves for the qualitative EIA and
ID were generated by numerous patients tested in
1 or 2 time periods, and a smaller number of
patients had multiple studies performed during the
course of a year. The CF curve is a composite of
patients receiving serial determinations of this
assay to assess for serologic response to infection
and treatment. P values for diﬀerences were
calculated using the Pearson v
2 test.
Results
Between January 1, 1999, and October 31, 2003,
360 patients had symptomatic, conﬁrmed, or
probable coccidioidomycosis with an identiﬁable
onset of symptoms. Of these patients, 298 were
immunocompetent and 62 were immunocompro-
mised. Table 1 summarizes the characteristics of
these patients and their coccidioidal variables.
These 360 patients had a total of 1,797 serologic
tests performed in our laboratory, and 314 of the
360 patients had serologic studies within the ﬁrst
year of symptom onset.
The Figure depicts the temporal sequence
curves for EIA, CF, ID, and all tests combined
for these patients. It compares the seroreactivity
among immunocompromised and immunocom-
petent hosts.
Table 2 summarizes the serologic results for
EIA, CF, and ID among the diﬀerent groups of
immunocompromised hosts. These results are also
compared with those for 252 immunocompetent
patients who were tested within the ﬁrst year of
symptom onset. In the immunosuppressed group,
no single test was 100% sensitive for all groups,
although the CF test was 100% sensitive for the
‘‘otherimmunocompromised’’group(10positiveof
10tested).Thissametestwasnotsensitivefororgan
transplantation(2positiveof6tested),andithadan
overall sensitivity of only 67% (35 of 52) (Fig. 1).
Discussion
Immune competence plays a clear role in the
clinical course and control of coccidioidomycosis,
initially with innate immunity and subsequently
with adaptive immunity aﬀorded by the TH1-
mediated immune response [12]. Numerous studies
have demonstrated an increased likelihood of
severe or disseminated infection among persons
with compromised immunity [7,10,13].
The diagnosis of coccidioidomycosis can be
challenging, whether patients are immunocompe-
tent or immunosuppressed. Typical symptoms and
radiographic ﬁndings are often nonspeciﬁc and
resemble pulmonary infection from other organ-
isms. Many patients with coccidioidomycosis have
a nonproductive cough, and sputum samples can
be diﬃcult to obtain for culture without an invasive
319procedure. A histopathologic diagnosis generally
requires tissue obtained by an invasive procedure.
Newer diagnostic methods under development
include polymerase chain reactions [14] and assays
to assess the cellular immune response to coccidi-
oidomycosis [15]; the ultimate utility of these tests
in the everyday diagnosis of this infection is not
clear at this time.
Table 1. Characteristics of 360 immunosuppressed and immunocompetent patients with symptomatic coccidioidomycosis
Variable ICH (N = 62) Non-ICH (N = 298) P value
No. (%) 95% CI No. (%) 95% CI
Patient characteristics
Age, y (mean±SD) 64.8±13.9 56.8±16.2 <.001
Male sex 39 (63) 51–75 157 (53) 47–58 .14
White race 57 (92) 85–99 238 (80) 75–84 .03
Patient medical history
Cancer 33 (53) 41–66 60 (20) 16–25 <.001
Cardiovascular disease 36 (58) 46–70 120 (40) 35–46 .01
Tobacco use 34 (55) 42–67 156 (52) 47–58 .72
Diabetes mellitus 15 (24) 14–35 40 (13) 10–17 .03
HIV infection 4 (6) 0–13 0 (0) 0 (0) <.001
Rheumatologic illness 13 (21) 11–31 20 (7) 4–10 <.001
Organ transplantation 7 (11) 3–19 0 (0) 0 (0) <.001
Hematologic malignancy 14 (23) 12–33 0 (0) 0 (0) <.001
Nonhematologic malignancy 19 (31) 19–42 68 (23) 18–28 .3
Coccidioidal illness
Lungs only 39 (63) 51–75 231 (78) 73–82 .02
Limited to thoracic cavity 50 (81) 71–90 267 (90) 86–93 .048
Extrathoracic dissemination 12 (19) 10–29 31 (10) 7–14 .048
Conﬁrmed by positive microbiologic or histologic tests 32 (52) 39–64 80 (27) 22–32 <.001
CI, conﬁdence interval; ICH, immunocompromised; non-ICH, nonimmunocompromised; HIV, human immunodeﬁciency virus.
Table 2. Seropositivity among 62 immunocompromised hosts with serologic conﬁrmation of coccidioidomycosis detected by various
serologic tests
Category of immunosuppression Type of serologic testing, no. (%)
EIA (IgM
and IgG)
CF ID (IgM or
IgG or both)
Any test
Tested Positive Tested Positive Tested Positive Tested Positive
Hematologic malignancy (N = 14) 12 4 (33) 10 6 (60) 6 1 (17) 12 8 (67)
Cancer and chemotherapy, nonhematologic (N = 19) 18 13 (72) 18 12 (67) 15 9 (60) 19 18 (95)
HIV infection (N = 4) 4 1 (25) 3 2 (67) 3 2 (67) 4 3 (75)
Organ transplantation (N = 7) 7 5 (71) 6 2 (33) 3 0 (0) 7 5 (71)
Rheumatologic illness (N = 13) 11 9 (82) 10 6 (60) 8 4 (50) 11 10 (91)
Other ICH illness
* (N = 11) 10 9 (90) 10 10 (100) 8 6 (75) 10 10 (100)
All patients
 57 38 (67) 52 35 (67) 40 21 (53) 58 49 (84)
Healthy patients tested £ 1 y after symptom
onset (N = 261)
244 212 (87) 252 188 (75) 248 180 (73) 261 247 (95)
CF, complement ﬁxation; EIA, enzyme immunoassay; ICH, immunocompromised; ID, immunodiﬀusion; HIV, human immunode-
ﬁciency virus.
*Patients with other causes of immunocompromise include 3 inﬂammatory bowel disease (1 taking inﬂiximab), 2 autoimmune blood
dyscrasias (hemolytic anemia and idiopathic thrombocytopenic purpura) taking prednisone, 1 autoimmune polyneuropathy, and 5
taking corticosteroids long-term for sarcoid, cough, other pulmonary diseases (chronic obstructive pulmonary disease, interstitial
pulmonary ﬁbrosis, or normal interstitial pneumonia).
Six patients have 2 immunosuppressive illnesses and are represented in each category.
320Figure 1. Temporal sequence of serologic responses after onset of symptoms in immunocompromised (ICH) versus nonimmuno-
compromised (non-ICH) patients with symptomatic coccidioidomycosis. Percentage of patients positive for coccidioidomycosis, A,b y
enzyme immunoassay for IgM; B, by enzyme immunoassay for IgG; C, by complement ﬁxation; D, by immunodiﬀusion; and, E,b y
any test.
321Serologic tests therefore play an important role
in the diagnosis and follow-up of patients with
coccidioidomycosis. For decades, assays have been
used to detect early IgM antibodies and later IgG
antibodies. Although many assay methods have
been used in the past, the most commonly used
IgM serologic methods now include ID and EIA,
whereas commonly used IgG methods include ID,
quantitative ID, CF, and EIA. Some authors have
reported a good correlation of the EIA with more
traditional assays [16]; others have noted potential
problems with speciﬁcity and have emphasized the
need for conﬁrmation by ID [6]. The EIA and ID
assays used in our laboratories are qualitative
tests, whereas the CF is a quantitative test that is
useful in following the course of illness over time;
quantitative results are best interpreted when
specimens from diﬀerent time points are analyzed
simultaneously [5]. Some reference laboratories
oﬀer a quantitative ID (IDCF) for late IgG, which
also allows a quantitative result. Titer results may
vary from laboratory to laboratory, which can
hinder interpretation; therefore, quantitative
studies performed serially are best interpreted if
performed by the same laboratory.
It is important to note that the sensitivity of
any assay in either compromised or healthy per-
sons is modest at best, regardless of when the
patient is tested relative to the onset of symptoms.
When serologic studies are so heavily relied upon
to make a diagnosis, negative studies can delay
diagnosis, result in the need for invasive testing,
and delay initiation of therapy. Since all our
patients had conﬁrmed or probable coccidioido-
mycosis, speciﬁcity of the test is not addressed in
this study.
In a few situations, the sensitivity of the EIA
appears to be greater than that of the CF or ID
tests, raising some concern that these cases repre-
sent false-positive ﬁndings. However, when we
analyzed the subgroup of patients whose diagnosis
of coccidioidomycosis was conﬁrmed with positive
histopathologic or microbiologic results, the rela-
tive positivity among the various serologic meth-
ods did not change (data not shown).
Although the magnitude of the ﬁnding is
unclear, previous authors have observed a
decreased serologic response in immunocompro-
mised hosts who contract coccidioidomycosis
[3,7–9,17]. Some of these studies examined 1 or 2
methods performed in reference laboratories.
Other authors reported the ability of immuno-
compromised hosts to mount an adequate sero-
logic response by CF, but the height of the titer
may be blunted when compared with that of
immunocompetent patients [10]. Our study evalu-
ated 3 diﬀerent methods, a locally performed EIA
and a CF and ID sent to an external reference
laboratory. For the present study, serum samples
for CF were sent to 1 of 2 diﬀerent reference lab-
oratories even for individual patients during their
course of illness, which made the quantitative
diﬀerences between immunocompetent and
immunocompromised persons diﬃcult to inter-
pret; we subsequently opted not to pursue this line
of evaluation.
Our study summarized the seroreactivity of
patients as a function of time since symptom onset
and compared the results of various serologic tests
between immunocompetent patients and immu-
nosuppressed hosts. The curves for the qualitative
EIA and ID are composite curves generated by
numerous patients tested in 1 or more time periods
over the course of a year; on the basis of our
observations in this study, we agree with other
authors that there is often little to be gained by
repeating a positive qualitative test [5]. The CF
curve is a composite of patients receiving serial
determinations of this assay to assess for a sero-
logic response to infection or treatment. In nearly
every comparison time point, immunocompetent
patients had a higher overall rate of seropositivity
for each of the diﬀerent serologic methods but
only a few data points achieved statistical signiﬁ-
cance. This ﬁnding likely reﬂects either no (or
small) diﬀerence between the groups or small or
heterogeneous cohorts or both. Even when all the
test results were combined, we did not ﬁnd a sig-
niﬁcantly decreased rate of seropositivity in the
immunocompromised group. In fact, there
appeared to be a higher rate of seropositivity when
all methods were considered than when each test
was considered alone. In light of the increased
sensitivity of a panel of tests compared with any
single test, it may be prudent to test immuno-
compromised patients by multiple methods
before concluding that a patient is seronegative.
A long-established method for improving the
yield of serologic testing has been to concentrate
serum before the test, which is recommended [5]
and practiced in the 2 reference laboratories
we use.
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patients had diﬀerences in seropositivity, ranging
from those with hematologic malignancy (overall
seropositivity, 69%) to a 100% seropositive rate in
the miscellaneous group of immunosuppressed
patients. This observation most likely reﬂects
inherent diﬀerences in the immune capabilities of
each group, but the groups were too small to
enable us to draw deﬁnitive conclusions.
Weaknesses of this study were its retrospective
nature and tertiary-care bias. This study did not
attempt to correlate the laboratory results to the
clinical course of patients. Many patients were
evaluated by numerous physicians, and the num-
ber and choices of serologic studies were those
deemed appropriate on a case-by-case basis. The
time of the patients’ initial evaluation at our
medical center in relation to the onset of their
symptoms varied from a few days to several
months. Serum samples were taken at various
times during the patient’s illness, and there was no
uniformity in the types of serologic tests ordered
by diﬀerent physicians. Therefore, each point in
the time line may represent a diﬀerent cohort of
patients and simply reﬂect the positivity of the test
at that particular time for the patients tested. A
large prospective study of serologic evaluations
over time would address some of these issues. The
referral center bias is evident in the number of
extrapulmonary infections observed in the healthy
population as well as by the large percentage of
biopsy- or culture-proven infections.
Inherent problems also exist when patients with
so many diﬀerent types of immunosuppressant
illnesses or treatments are grouped into a single
cohort. In this study, the many diﬀerent illnesses
and their immunosuppressant-inducing treatments
included hematologic malignancies, cancer che-
motherapy, organ or stem cell transplantation,
human immunodeﬁciency virus infection, and
numerous systemic illnesses (such as connective
tissue diseases) requiring therapy with immune
modiﬁers. These patients may have had various
immune defects, some of which may or may not be
important in the detection or control of coccidi-
oidomycosis. In addition, some patients (e.g.,
organ transplant recipients) may have varying
levels of immunosuppression throughout the
course of the illness, with marked immune
impairment early on and less impairment over
time. None of these diﬀerences was taken into
account in the analysis of the immunocompro-
mised group in this study, and these diﬀerences
may be an important barrier to detection of sig-
niﬁcant diﬀerences in seroreactivity. In addition,
the immunocompromised group was older and
had more comorbid illness than the noncompro-
mised cohort, factors that again impede compari-
son of the 2 groups.
In summary, our evaluation of coccidioidal
serologic tests among 360 immunocompetent and
immunosuppressed patients using 1,797 serologic
samples showed that, for any single serologic test,
immunocompetent hosts appeared to be more
likely than immunosuppressed patients to be
seropositive with active coccidioidomycosis. When
the test results from 3 diﬀerent methods were
considered as a whole, the sensitivity of the sero-
logic evaluation increased in the immunocompro-
mised patients, but this overall result was not
statistically diﬀerent for immunosuppressed versus
immunocompetent persons. Immunosuppressed
persons have the ability to mount a serologic
response to coccidioidomycosis, but multiple
methods may be required to detect that seroposi-
tivity. Future prospective studies evaluating large
homogeneous cohorts may further clarify these
results.
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